Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma

Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma

Brain tumours kill more children and adults under 40 than any other cancer, with approximately half of primary brain tumours being diagnosed as high-grade malignancies known as glioblastomas. Despite de-bulking surgery combined with chemo-/radiotherapy regimens, the mean survival for these patients...

Full description

Bibliographic Details
Main Authors: Natasha Carmell, Ola Rominiyi, Katie N. Myers, Connor McGarrity-Cottrell, Aurelie Vanderlinden, Nikita Lad, Eva Perroux-David, Sherif F. El-Khamisy, Malee Fernando, Katherine G. Finegan, Stephen Brown, Spencer J. Collis
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
ERK5
MAPK7
glioblastoma
temozolomide
DNA damage
sensitisation
Online Access:https://www.mdpi.com/2072-6694/13/5/944

Similar Items

Similar Items